GUCY1B2
ENSG00000123201
Target class
Enzyme
Chromosome
13
Approved drugs
8
Clinical candidates (approved and in development)
14
- Approved drugs
- 8
- Clinical candidates (approved and in development)
- 14
- Chemical probe available
- No
- Target name
- GUCY1B2
- Gene name
- Guanylate cyclase 1 soluble subunit beta 2 (pseudogene)
- Gene symbol
- GUCY1B2
- Protein name
- Guanylate cyclase soluble subunit beta-2 (GCS-beta-2) (EC 4.6.1.2)
- GUCY1B2P
- GC-SB2
- Gene biotype
- Transcribed unitary pseudogene
- Gene family
- Soluble guanylate cyclases|Unitary pseudogenes
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 1.48
- Tissue specificity (Gini)
- 0.605
- Tissue specificity (tau)
- 0.944
- R-HSA-392154
- R-HSA-445355
- End position
- 51062894
- Start position
- 51006991
- Chromosome
- 13
- Strand
- Reverse
- Cytoplasm.
- Tissue specificity (tau)
- 0.944161
- Expression inequality (Gini)
- 0.605486
Expression in transcripts per million
- Spleen
- 1.48
- Kidney - Medulla
- 0.55
- Testis
- 0.38
- Kidney - Cortex
- 0.32
- Lung
- 0.16
Expression in transcripts per million
- Spleen1.48
- Kidney - Medulla0.55
- Testis0.38
- Kidney - Cortex0.32
- Lung0.16
- Brain - Cerebellum0.14
- Small Intestine - Terminal Ileum0.14
- Skin - Sun Exposed (Lower leg)0.14
- Brain - Cerebellar Hemisphere0.14
- Bladder0.13
- Nerve - Tibial0.12
- Fallopian Tube0.12
- Adipose - Visceral (Omentum)0.11
- Uterus0.11
- Breast - Mammary Tissue0.11
- Colon - Transverse0.11
- Adipose - Subcutaneous0.1
- Pituitary0.1
- Prostate0.1
- Vagina0.1
- Skin - Not Sun Exposed (Suprapubic)0.09
- Thyroid0.08
- Cervix - Ectocervix0.08
- Minor Salivary Gland0.07
- Esophagus - Muscularis0.07
And 29 more, listed on the interactive page.
Cellular components
- GO:0005829
Related records
Trials (597)
- : Vascular Function in Health and Disease
- "Lignocaine vs GTN Ointment for Postoperative Pain After Hemorrhoidectomy")
- 1H Magnetic Resonance Spectroscopy in Migraine Patients
- 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
- A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants
- A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects
- A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis
- A Cohort Prospective Study of Predictors Influencing the Quality of Visualization of the Operating Field During Orthognathic Surgery
- A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control
- A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers
- A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis
- A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
- A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade
- A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
- A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
- A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
- A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
- A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia
- A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
- A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately
Drugs (14)
- Ataciguat Soluble guanylate cyclase activator
- Cinaciguat Soluble guanylate cyclase activator
- Isosorbide dinitrate Soluble guanylate cyclase activator
- Isosorbide mononitrate Soluble guanylate cyclase activator
- Methylene blue anhydrous Soluble guanylate cyclase inhibitor
- Nitric oxide Soluble guanylate cyclase activator
- Nitroglycerin Soluble guanylate cyclase activator
- Olinciguat Soluble guanylate cyclase positive allosteric modulator
- Pentaerythritol tetranitrate Soluble guanylate cyclase activator
- Praliciguat Soluble guanylate cyclase activator
- Riociguat Soluble guanylate cyclase positive allosteric modulator
- Runcaciguat Soluble guanylate cyclase activator
- Sodium nitroprusside Soluble guanylate cyclase activator
- Vericiguat Soluble guanylate cyclase activator